Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has been featured in a NetworkNewsAudio Audio Press Release titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth,” highlighting the company's leadership and innovative drug development efforts. The release underscores the role of chair and CEO Dr. Vuong Trieu, who has filed more than 500 patent applications and holds 75 issued patents spanning oncology, immunotherapy, and nanomedicine. Dr. Trieu previously developed Abraxane(R), a nanotechnology-based formulation that transformed treatment for breast, lung, and pancreatic cancers, and advanced Cynviloq(TM), a novel micellar paclitaxel therapy. The feature emphasizes how his track record and expertise position Oncotelic to advance pioneering therapies with strong market potential.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by Dr. Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. The company also licenses and codevelops select drug candidates through joint ventures, including a 45% ownership in GMP Bio, a joint venture under Trieu’s leadership that advances its own pipeline of drug candidates complementing Oncotelic’s strategic position in oncology and rare disease therapeutics.
The NetworkNewsAudio APR provides investors with insights into the company's strategic direction and the potential impact of its pipeline. The full press release is available at https://ibn.fm/2Ir6y. For more information about Oncotelic Therapeutics, including the latest news and updates, visit the company’s newsroom at https://ibn.fm/OTLC.
The feature is distributed by InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @IBN that offers advanced wire-grade press release syndication and a range of corporate communications solutions. InvestorWire provides access to a vast network of wire solutions, article syndication to over 5,000 outlets, enhanced press release distribution, and social media distribution to millions of followers. The company is based in Austin, Texas, and can be reached at its office via the InvestorWire website. The full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
